Abstract:The diselenide bond has attracted intense interest in redox-responsive drug delivery systems (DDSs) in tumor chemotherapy, due to its higher sensitivity than the most investigated bond, namely the disulfide bond. Here, a diselenide-bridged doxorubicin dimeric prodrug (D-DOXSeSe) was designed by coupling two doxorubicin molecules with a diselenodiacetic acid (DSeDAA) molecule via α-amidation, as a redox-triggered drug self-delivery system (DSDS) for tumor-specific chemotherapy. The drug release profiles indicated that the D-DOXSeSe could be cleaved to release the derivatives selenol (DOX-SeH) and seleninic acid (DOX-SeOOH) with the triggering of high GSH and H2O2, respectively, indicating the double-edged sword effect of the lower electronegativity of the selenide atom. The resultant solubility-controlled slow drug release performance makes it a promising candidate as a long-acting DSDS in future tumor chemotherapy. Moreover, the interaction between the conjugations in the design of self-immolation traceless linkers was also proposed for the first time as another key factor for a desired precise tumor-specific chemotherapy, besides the conjugations themselves.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the specificity of chemotherapeutic drugs in tumor treatment and reduce their toxic side effects on normal cells. Specifically, the authors designed a doxorubicin dimer prodrug (D - DOX SeSe) bridged by diselenide bonds to achieve this goal by combining α - amide bonds and diselenide bonds. This prodrug can release the drug under the trigger of high - concentration glutathione (GSH) or hydrogen peroxide (H₂O₂), thereby achieving drug release specific to the tumor microenvironment. The paper also explored the synthesis method, characterization of this prodrug, the preparation of nanoparticles and its drug - release behavior under different conditions, as well as its uptake at the cellular level and selective cytotoxicity. ### Main problems solved by the paper: 1. **Improve the tumor specificity of drugs**: By designing a new type of doxorubicin dimer prodrug bridged by diselenide bonds, it can respond to specific stimuli in the tumor microenvironment (such as high - concentration GSH and H₂O₂), thereby achieving specific drug release and reducing the toxic side effects on normal cells. 2. **Improve the water - solubility and stability of drugs**: By connecting two doxorubicin molecules with diselenodiacetic acid (DSeDAA) molecules through α - amide bonds, a stable dimer prodrug is formed, which improves the water - solubility and stability of the drug. 3. **Optimize drug - release kinetics**: The drug - release behavior under different conditions (such as different pH values, GSH and H₂O₂ concentrations) was studied, and it was found that this prodrug can slowly and continuously release the drug in the tumor microenvironment, avoiding premature leakage of the drug in normal tissues. 4. **Explore the design of self - immolative traceless linkers**: The importance of considering conjugate interactions when designing self - immolative traceless linkers was proposed. Besides conjugation itself, this is also one of the key factors for achieving precise tumor - specific chemotherapy. ### Main conclusions: - Through the combination of α - amide bonds and diselenide bonds, D - DOX SeSe was successfully synthesized and characterized by means such as nuclear magnetic resonance (NMR) and ultraviolet - visible spectroscopy (UV - Vis). - Triggered by high - concentration GSH or H₂O₂, D - DOX SeSe can release doxorubicin derivatives (selenol DOX - SeH and selenic acid DOX - SeOOH), achieving drug release specific to the tumor microenvironment. - Studies have shown that this prodrug exhibits good stability and controllable drug - release behavior under the conditions simulating the tumor microenvironment, and has potential clinical application value. Through these studies, the paper provides new ideas and methods for the development of more efficient and safer tumor chemotherapeutic drugs.

Diselenide-Bridged Doxorubicin Dimeric Prodrug: Synthesis and Redox-Triggered Drug Release